Merck Serono to build production facility in China

11/18/2013 | Genetic Engineering & Biotechnology News

Merck Serono plans to invest $107 million to construct a 430,556-square-foot biopharmaceutical manufacturing site in Shanghai. The facility will be the company's second-largest in the world and will manufacture Merck's leading heart- and metabolic-disease treatments including diabetes drug Glucophage, thyroid drug Euthyrox and heart treatment Concor. Construction is set to begin next year and be finished in 2016.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ